
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
ZC3HC1 (zinc finger C3HC-type containing 1) encodes an F-box-containing protein that functions as a component of an SCF-type E3 ubiquitin ligase complex. The complex regulates cell-cycle progression by targeting cyclin B1 for ubiquitin-mediated degradation, thereby controlling the transition from G2 phase to mitosis. ZC3HC1 therefore contributes to regulation of cell-cycle timing through targeted protein degradation.
Papillary thyroid carcinoma is represented by TPC-1, a human thyroid cancer cell line established from a thyroid tumor. The cells are classified as a human papillary thyroid carcinoma model and carry the characteristic RET/PTC1 rearrangement resulting from fusion of RET with CCDC6. TPC-1 is widely used for studies of thyroid cancer biology and RET-associated oncogenic signaling.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_001282191
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?